Um Serviço de Desenvolvimento de Identidade de Género pode ser uma espécie de clínica do Dr. Mengele (2)

Continuação de (1)

Desde o Homo sapiens sapiens das savanas se sabe que a puberdade e a adolescência são caracterizadas por instabilidade resultante de uma intensa carga hormonal. Por isso, as sociedades primitivas tinham rituais e processos sociais de iniciação dos jovens no mundo adulto. Uma das invenções da "identidade de género", uma modalidade do politicamente correcto, tem consistido em aproveitar a puberdade e a adolescência para induzir nos jovens a ideia de que se não se sentem bem no seu corpo deverão migrar para outro "género". 

A chamada medicina do género foi inventada para lidar com essa migração e hoje alguns países criaram instituições que lhe são dedicadas,  como o Tavistock Centre da Tavistock and Portman NHS Foundation Trust britânico. As terapias consistem principalmente na administração de drogas bloqueadoras da puberdade com efeitos por vezes desastrosos na saúde, ao ponto que nalguns países pioneiros na manipulação hormonal se começa a questionar essas terapias.
 
«Last June, though, Finland revised its guidelines to prefer psychological treatment to drugs. In September Britain launched a top-down review of the field. In December the High Court of England and Wales ruled that under-16s were unlikely to be able to consent meaningfully to taking puberty blockers, leading gids to suspend new referrals, though a subsequent ruling held that parents could consent on their children's behalf. On April 6th Arkansas passed laws that make prescribing puberty blockers and cross-sex hormones to children illegal. Also in April the Astrid Lindgren Children's Hospital in Stockholm, a part of the Karolinska Institute, announced that it would stop prescribing puberty blockers and cross-sex hormones to those under 18, except in clinical trials.

Those sceptical of affirmation therapy point out two problems. Evidence is lacking, and what exists is not reassuring. A review by Sweden's health authorities in 2019 found little research, mostly of poor quality. Britain’s National Institute for Health and Care Excellence found that puberty blockers did little to dispel gender dysphoria or improve patients' mental health (though they do not make such feelings worse). Moreover, existing studies suggest that, without intervention, most children with gender dysphoria end up reconciled to their natal sex as adults.

There is also evidence that the drugs may cause serious harm. One example is described by Michael Biggs of Oxford University in a letter published on April 26th in the Journal of Paediatric Endocrinology and Metabolism. Bone-mineral density (bmd) usually rises sharply in puberty. But of 24 gids patients who had been prescribed puberty blockers, a third had bmd scores in the bottom 2% of their age groups (more that two standard deviations below the mean, see chart).

One patient, who began puberty blockers aged 12, suffered four fractures by the age of 16. That medical history, says Dr Biggs, would usually be enough to diagnose osteoporosis—normally a disease of the elderly. Animal studies suggest puberty blockers may cause cognitive damage, too. Cross-sex hormones have been linked to heart disease, strokes and sterility.»

Doubts are growing about therapy for gender-dysphoric children